News

Reel change after change of scene
Enlarge image

BiopeopleUKAustria

Reel change after change of scene

15.05.2012 - F-Star's management has been lifted and replaced by a troika of new leaders.

Cambridge  - A press note issued by Austrian-British F-Star GmbH on 14 May names the new personnel. Following Keith Fitz-Gerald as CEO is John Haurum who had been CSO of the Danish biotechnology company Symphogen A/S. Also quickly appointed: Jane Dancer and Sharon Grimster. Dancer was previously employed at Cellzome Ltd. At F-Star she becomes Chief Operating Officer (COO).  Grimster, formerly employed at Antisoma plc, has been appointed Vice President of Development.

Clearing the management board so vigorously  is indeed a surprise, even with the knowledge that the company - a leader in the development of bispecific antibodies - has had a hard time after moving all research operations from Vienna to Cambridge leaving the parent company in Austria. The Supervisory Board did not forget to mention Kevin FitzGerald and thanked him for "his significant contribution in bringing F-star to its current stage of development". He started as the company's CEO in May 2009. Within this three years, the start-up saved €23m using venture financing. He also arranged major alliances with Boehringer Ingelheim and Merck Serono.


With its proprietary technology, F-star produces antibody fragments called Fcabs, which have full antibody capabilities but are believed to have a better biological profile because of their small size. Additionally Fcabs may offer IP advantages in many cases by lacking variable regions, which may be claimed by third party antibody patents. This seems to attract pharma companies. In November 2010, F-star allied with Germany's Boehringer Ingelheim and in September 2011 with Merck Serono.

http://www.european-biotechnology-news.com/news/news/2012-02/reel-change-after-change-of-scene.html

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • 4SC (D)3.25 EUR8.33%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-7.56%
  • RENEURON (UK)3.50 GBP-5.41%
  • OXFORD BIOMEDICA (UK)5.62 GBP-4.91%

TOP

  • THERAMETRICS (CH)0.03 CHF50.0%
  • GALAPAGOS (B)52.00 EUR29.9%
  • NICOX (F)10.91 EUR26.6%

FLOP

  • BIONOR PHARMA (N)0.68 NOK-23.6%
  • MOBERG PHARMA (S)38.60 SEK-22.0%
  • BIOCARTIS GROUP NV (B)8.15 EUR-20.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.00 SEK1953.0%
  • NICOX (F)10.91 EUR486.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-88.8%
  • BB BIOTECH (D)43.82 EUR-84.9%
  • BIOTEST (D)17.14 EUR-77.7%

No liability assumed, Date: 26.05.2016